Pharvaris (NASDAQ:PHVS) Price Target Increased to $42.00 by Analysts at Oppenheimer

Pharvaris (NASDAQ:PHVS) had its target price boosted by Oppenheimer from $38.00 to $42.00 in a report published on Friday morning, Benzinga reports. They currently have an outperform rating on the stock.

Separately, Wedbush dropped their price objective on Pharvaris from $35.00 to $31.00 and set an outperform rating on the stock in a research note on Thursday, May 9th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of Moderate Buy and a consensus target price of $33.60.

Pharvaris Trading Up 0.1 %

NASDAQ PHVS opened at $19.12 on Friday. The business’s 50-day moving average price is $17.73 and its two-hundred day moving average price is $20.29. Pharvaris has a 12 month low of $15.00 and a 12 month high of $33.00. The firm has a market capitalization of $608.78 million, a PE ratio of -7.13 and a beta of -3.10.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.02). As a group, analysts forecast that Pharvaris will post -2.58 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Blackstone Inc. acquired a new position in shares of Pharvaris in the 4th quarter valued at about $2,805,000. Commodore Capital LP acquired a new position in Pharvaris during the 4th quarter worth approximately $22,440,000. venBio Partners LLC raised its stake in Pharvaris by 15.4% during the 4th quarter. venBio Partners LLC now owns 4,919,504 shares of the company’s stock worth $137,992,000 after buying an additional 654,832 shares during the period. Novo Holdings A S raised its stake in Pharvaris by 47.7% during the 2nd quarter. Novo Holdings A S now owns 1,725,000 shares of the company’s stock worth $32,430,000 after buying an additional 556,970 shares during the period. Finally, Deerfield Management Company L.P. Series C raised its stake in Pharvaris by 31.6% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 1,397,279 shares of the company’s stock worth $26,269,000 after buying an additional 335,687 shares during the period.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.